Orogen Royalties Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.organon.com
- Introduction
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
Extension Study of Asenapine [P06107 (NCT01244815)] for Pediatric Bipolar Disorder (P05898)
- First Posted Date
- 2011-05-09
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 322
- Registration Number
- NCT01349907
Bioequivalence of Nomegestrol Acetate (NOMAC) and Estradiol (E2) in Commercial Versus Phase 3 Pivotal Clinical Batches of NOMAC-E2 Tablets (P06328)
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-05-02
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 158
- Registration Number
- NCT01345786
A Study to Evaluate Fasting/Postprandial Serum Apolipoprotein B-48 (ApoB-48) Levels in Diabetic Participants With Normal to Moderately High Low Density Lipoprotein-C (LDL-C) Levels (MK-0653A-259 AM1)
- First Posted Date
- 2011-04-12
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 93
- Registration Number
- NCT01333436
- Locations
- 🇰🇷
MSD Korea Ltd., Seoul, Korea, Republic of
Safety of Etoricoxib (MK-0663) in Patients With Spondyloarthropathy (SpA)/Ankylosing Spondylitis (AS) in Sweden (EP07013.013.11.082)
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-04-01
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 21108
- Registration Number
- NCT01327638
MK-0954A in Japanese Patients With Essential Hypertension Not Adequately Controlled With Losartan (MK-0954A-352)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-03-02
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 336
- Registration Number
- NCT01307046
A Long-term Study of the Safety of MK-0954A in Patients With Essential Hypertension (MK-0954A-351)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-03-02
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 278
- Registration Number
- NCT01307033
Post-Marketing Surveillance of the Safety and Efficacy of Orgalutran (Ganirelix)®
- First Posted Date
- 2011-02-25
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 711
- Registration Number
- NCT01304511
Survey of Osteoarthritis Real World Therapies (MK-0663-140)
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-02-11
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 1261
- Registration Number
- NCT01294696
Long-Term Exposure to Rizatriptan 5-mg and 10-mg Oral Tablet (Combined Extension Protocols MK-0462-022, MK-0462-025, MK-0462-029)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-01-31
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 1959
- Registration Number
- NCT01286207
Efficacy of Losartan + Amlodipine Compared to Amlodipine Alone in the Treatment of Uncontrolled High Blood Pressure (MK-0954F-399)
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-01-17
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 334
- Registration Number
- NCT01277822
© Copyright 2024. All Rights Reserved by MedPath